We have recently shown that insulin-resistant obese subjects exhibit i
mpaired endothelial function. Here, we test the hypothesis that elevat
ion of circulating FFA to levels seen in insulin-resistant subjects ca
n impair endothelial function, We studied leg blood flow responses to
graded intrafemoral artery infusions of the endothelium-dependent vaso
dilator methacholine chloride (Mch) or the endothelium-independent vas
odilator sodium nitroprusside during the infusion of saline and after
raising systemic circulating FFA levels esogenously via a low-or high-
dose infusion of Intralipid plus heparin or endogenously by an infusio
n of somatostatin (SRIF) to produce insulinopenia in groups of lean he
althy humans, After 2 h of infusion of Intralipid plus heparin, FFA le
vels increased from 562+/-95 to 1,303+/-188 mu mol, and from 350+/-35
to 3,850+/-371 mu mol (P < 0.001) vs. saline for both low-and high-dos
e groups, respectively, Mch-induced vasodilation relative to baseline
was reduced by similar to 20% in response to the raised FFA levels in
both groups (P < 0.05, saline vs, FFA, ANOVA). In contrast, similar FF
A elevation did not change leg blood flow responses to sodium nitropru
sside, During the 2-h SRIF infusion, insulin levels fell, and FFA leve
ls rose from 474+/-22 to 1,042+/-116 mu mol (P < 0.01); Mch-induced va
sodilation was reduced by similar to 20% (P < 0.02, saline vs, SRIF, A
NOVA). Replacement of basal insulin levels during SRIF resulted in a f
all of FFA levels from 545+/-47 to 228+/-61 mu mol, and prevented the
impairment of Mch-induced vasodilation seen with SRIF alone, In conclu
sion, (a) elevated circulating FFA levels cause endothelial dysfunctio
n, and (b) impaired endothelial function in insulin-resistant humans m
ay be secondary to the elevated FFA concentrations observed in these p
atients.